NCT04734275View on ClinicalTrials.gov

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

March 25, 2021

Study Completion Date

March 25, 2021

Conditions

Chronic Kidney Disease

Interventions

DRUG

AZD5718

Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.

Trial Locations (1)

HA1 3UJ

Research Site, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY